CA2197684A1 - Human-murine chimeric antibodies against respiratory syncytial virus - Google Patents

Human-murine chimeric antibodies against respiratory syncytial virus

Info

Publication number
CA2197684A1
CA2197684A1 CA2197684A CA2197684A CA2197684A1 CA 2197684 A1 CA2197684 A1 CA 2197684A1 CA 2197684 A CA2197684 A CA 2197684A CA 2197684 A CA2197684 A CA 2197684A CA 2197684 A1 CA2197684 A1 CA 2197684A1
Authority
CA
Canada
Prior art keywords
respiratory syncytial
syncytial virus
human
antibodies against
chimeric antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2197684A
Other languages
French (fr)
Other versions
CA2197684C (en
Inventor
Leslie Sid Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
Leslie Sid Johnson
Medimmune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leslie Sid Johnson, Medimmune, Inc. filed Critical Leslie Sid Johnson
Publication of CA2197684A1 publication Critical patent/CA2197684A1/en
Application granted granted Critical
Publication of CA2197684C publication Critical patent/CA2197684C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one muring monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection.
CA002197684A 1994-08-15 1995-08-09 Human-murine chimeric antibodies against respiratory syncytial virus Expired - Lifetime CA2197684C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/290,592 US5824307A (en) 1991-12-23 1994-08-15 Human-murine chimeric antibodies against respiratory syncytial virus
US08/290,592 1994-08-15
PCT/US1995/010053 WO1996005229A1 (en) 1994-08-15 1995-08-09 Human-murine chimeric antibodies against respiratory syncytial virus

Publications (2)

Publication Number Publication Date
CA2197684A1 true CA2197684A1 (en) 1996-02-22
CA2197684C CA2197684C (en) 2000-10-31

Family

ID=23116697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002197684A Expired - Lifetime CA2197684C (en) 1994-08-15 1995-08-09 Human-murine chimeric antibodies against respiratory syncytial virus

Country Status (11)

Country Link
US (4) US5824307A (en)
EP (3) EP0783525B1 (en)
JP (6) JP3896160B2 (en)
AT (1) ATE341563T1 (en)
AU (1) AU713113B2 (en)
CA (1) CA2197684C (en)
DE (1) DE69535253T2 (en)
DK (2) DK0783525T3 (en)
ES (2) ES2442460T3 (en)
PT (2) PT1659133E (en)
WO (1) WO1996005229A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704505B2 (en) 1994-08-15 2010-04-27 Medimmune, Llc Human-murine chimeric antibodies against respiratory syncytial virus
US9321831B2 (en) 2007-06-01 2016-04-26 Medimmune Limited RSV-specific binding molecules and means for producing them
US9879067B2 (en) 2002-06-14 2018-01-30 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US10035843B2 (en) 2009-10-06 2018-07-31 Medimmune Limited RSV-specific binding molecule

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
JP2002508940A (en) 1998-03-13 2002-03-26 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド Humanized antibodies and uses thereof
CO5280147A1 (en) * 1999-05-18 2003-05-30 Smithkline Beecham Corp MONOCLONAL HUMAN ANTIBODY
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) * 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20010034062A1 (en) * 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
CA2401652A1 (en) * 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
AU2001241918A1 (en) * 2000-03-02 2001-09-12 Med Immune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
CA2407292A1 (en) * 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
WO2001082965A1 (en) * 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies
EP2338512A1 (en) * 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2008202076B2 (en) * 2000-11-28 2011-09-08 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2435180C (en) 2001-01-19 2019-04-09 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
TWI344991B (en) 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
JP2005526769A (en) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Central airway administration for systemic delivery of therapeutic agents
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc Recombinant anti-interleukin-9 antibodies
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
ATE530577T1 (en) * 2002-05-10 2011-11-15 Purdue Research Foundation EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF
ATE525398T1 (en) * 2002-05-10 2011-10-15 Medimmune Inc EPHA2 MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHOD
AU2013201261B2 (en) * 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
JP2005533861A (en) * 2002-07-25 2005-11-10 メデュームン，インコーポレーテッド Therapies and prophylaxis of RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
AR047392A1 (en) * 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
CN102584947B (en) 2003-04-01 2014-03-12 国家健康医学研究所 Antibodies directed against hepatitis c virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions
JP2006523240A (en) * 2003-04-11 2006-10-12 メディミューン，インコーポレーテッド EphA2, hypoproliferative cell injury and epithelial and endothelial reconstitution
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 and non-neoplastic hyperproliferative cell disorders
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
US7704720B2 (en) * 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CN1813061B (en) * 2003-04-25 2013-05-29 免疫医疗有限责任公司 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
DE602005018325D1 (en) * 2004-02-19 2010-01-28 Genentech Inc ANTIBODIES WITH CORRECTED CDR
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
WO2006099360A2 (en) * 2005-03-10 2006-09-21 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US20060228367A1 (en) * 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
KR20080025174A (en) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 Antibody formulations having optimized aggregation and fragmentation profiles
CA2633718A1 (en) * 2005-12-21 2007-07-05 Medimmune, Llc Affinity optimized epha2 agonistic antibodies and methods of use thereof
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
EP2015632B1 (en) * 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Stable hydroalcoholic oral spray formulations and methods
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
SG170032A1 (en) 2006-08-28 2011-04-29 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
CA2673049C (en) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CN101801346A (en) * 2007-05-10 2010-08-11 诺瓦德尔药品公司 anti-insomnia compositions and methods
WO2009000098A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
US7867497B2 (en) * 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
DK2285408T3 (en) * 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
ES2884117T3 (en) 2008-06-25 2021-12-10 Novartis Ag Optimization of the solubility of immunobagulants
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
DK2464664T3 (en) 2009-08-13 2016-01-18 Crucell Holland Bv ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS FOR USING IT
JP5744196B2 (en) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー Anti-human respiratory polynuclear virus (RSV) antibodies and methods of use
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (en) 2010-10-01 2022-07-11 Modernatx Inc RIBONUCLEIC ACIDS CONTAINING N1-METHYL-PSEUDOURACIL AND USE THEREOF
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
EA201700111A1 (en) 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд POLYPEPTIDE STRUCTURES AND THEIR APPLICATION
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015516143A (en) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
LT2922554T (en) 2012-11-26 2022-06-27 Modernatx, Inc. Terminally modified rna
TWI659968B (en) * 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
WO2015118149A1 (en) * 2014-02-10 2015-08-13 Univercells Nv System, apparatus and method for anti-rsv antibodies and formulations
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9340604B1 (en) * 2014-10-29 2016-05-17 Aridis Pharmaceuticals, Inc. Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
EP3212510B1 (en) 2014-10-31 2020-12-09 Medlmmune, LLC Manufacturing method of a degassed composition
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
DE112016001013T5 (en) 2015-03-03 2017-12-21 Kymab Limited ANTIBODIES, USES AND METHODS
CL2015002152A1 (en) 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Monoclonal antibodies specific for the human syncytial respiratory virus (vrsh) antigen, produced and secreted by cellular hybridomas, useful for the detection and diagnosis of infection caused by vrsh
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
CA3040886A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3529272A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CA3040893A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
BR112021000934A2 (en) 2018-07-20 2021-04-27 Pierre Fabre Medicament receiver for sight
WO2021005232A1 (en) 2019-07-11 2021-01-14 Umc Utrecht Holding B.V. Intranasal administration of neutralising antiviral antibodies
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517304A (en) 1980-07-01 1985-05-14 National Research Development Corporation Production of viral antigens
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US4717766A (en) * 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
AU617739B2 (en) 1987-12-23 1991-12-05 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
EP0583356B1 (en) 1991-05-01 2002-07-31 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5240694A (en) 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1993019197A1 (en) 1992-03-20 1993-09-30 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
AU686113B2 (en) 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
AU3660893A (en) * 1993-01-29 1994-08-15 Med Immune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704505B2 (en) 1994-08-15 2010-04-27 Medimmune, Llc Human-murine chimeric antibodies against respiratory syncytial virus
US8562994B2 (en) 1994-08-15 2013-10-22 Medimmune, Llc Human-murine chimeric antibodies against respiratory syncytial virus
US9879067B2 (en) 2002-06-14 2018-01-30 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US10604560B2 (en) 2002-06-14 2020-03-31 Arexis Ab Stabilized liquid anti-RSV antibody formulations
US11180542B2 (en) 2002-06-14 2021-11-23 Arexis Ab Stabilized liquid anti-RSV antibody formulations
US9321831B2 (en) 2007-06-01 2016-04-26 Medimmune Limited RSV-specific binding molecules and means for producing them
US10059757B2 (en) 2007-06-01 2018-08-28 Medimmune Limited RSV-specific binding molecules and means for producing them
US10730931B2 (en) 2007-06-01 2020-08-04 Medimmune Limited RSV-specific binding molecules and means for producing them
US10035843B2 (en) 2009-10-06 2018-07-31 Medimmune Limited RSV-specific binding molecule
US10723786B2 (en) 2009-10-06 2020-07-28 Medimmune, Limited RSV-specific binding molecule

Also Published As

Publication number Publication date
AU713113B2 (en) 1999-11-25
JPH10504195A (en) 1998-04-28
JP2006265263A (en) 2006-10-05
DK1659133T3 (en) 2014-01-27
WO1996005229A1 (en) 1996-02-22
US7704505B2 (en) 2010-04-27
JP2010241819A (en) 2010-10-28
DK0783525T3 (en) 2007-02-05
PT1659133E (en) 2014-01-20
US8562994B2 (en) 2013-10-22
US20090104205A1 (en) 2009-04-23
CA2197684C (en) 2000-10-31
US20140093501A1 (en) 2014-04-03
US20120156195A1 (en) 2012-06-21
EP0783525A1 (en) 1997-07-16
US5824307A (en) 1998-10-20
EP1659133B1 (en) 2013-10-16
EP0783525A4 (en) 2000-08-30
JP4216297B2 (en) 2009-01-28
JP3896160B2 (en) 2007-03-22
JP2009029817A (en) 2009-02-12
EP2371858A3 (en) 2011-10-26
JP2008024707A (en) 2008-02-07
ES2442460T3 (en) 2014-02-11
ES2274518T3 (en) 2007-05-16
DE69535253D1 (en) 2006-11-16
EP1659133A2 (en) 2006-05-24
EP1659133A3 (en) 2009-01-21
AU3215895A (en) 1996-03-07
EP2371858A2 (en) 2011-10-05
PT783525E (en) 2007-01-31
JP2012207022A (en) 2012-10-25
DE69535253T2 (en) 2007-05-16
ATE341563T1 (en) 2006-10-15
EP0783525B1 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
EP2371858A3 (en) Human-Murine chimeric antibodies against respiratory syncytial virus
IL135221A0 (en) Natural humanized antibody and methods for the preparation thereof
AU4399297A (en) Reconstituted human anti-hm1.24 antibody
EP0804237B8 (en) Humanized antibodies against leukocyte adhesion molecule vla-4
FR12C0004I1 (en)
AU5647896A (en) Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
NZ614727A (en) Human antibodies that bind human tnfa
CA2192512A1 (en) Nm03 antibody materials and methods
WO2002055668A3 (en) Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1f7
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
CA2106719A1 (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
MX9301858A (en) RECOMBINANT HIV-HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF HIV INFECTION.
AU4441393A (en) Granulocyte-binding antibody fragments, their preparation and use
CA2063872A1 (en) Pharmaceutical preparation based on plasma proteins
AU3660893A (en) Human-murine chimeric antibodies against respiratory syncytial virus
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
AU627540B2 (en) Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof
CA2079230A1 (en) Bcrf1 antagonists for treating epstein-barr virus infections

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150810